Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Follicular lymphoma: BR in the frontline and pre-treatment PET

Paolo Strati • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Brentuximab vedotin Rituximab

Paolo Strati, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of BR vs. R-CHOP as an initial treatment for advanced follicular lymphoma (FL), and the prognostic value of a pre-treatment PET scan in FL patients receiving frontline therapy. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Paolo Strati

Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists 31:23
Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists
Andrew Jallouk et al. • 23 Sep 2025
Acalabrutinib in combination with rituximab & lenalidomide in R/R follicular lymphoma 1:27
Acalabrutinib in combination with rituximab & lenalidomide in R/R follicular lymphoma
Paolo Strati • 19 Jun 2025
The evolving role of autoSCT for B-cell lymphoma in the era of CAR-T & selecting patients for SCT 2:28
The evolving role of autoSCT for B-cell lymphoma in the era of CAR-T & selecting patients for SCT
Paolo Strati • 18 Jun 2025
Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more 48:01
Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more
Gloria Iacoboni et al. • 28 Mar 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals